Beigene Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BEIGENE, and when can generic versions of BEIGENE drugs launch?
BEIGENE has one approved drug.
There are nine US patents protecting BEIGENE drugs.
There are fifty-six patent family members on BEIGENE drugs in twenty-eight countries and eleven supplementary protection certificates in eleven countries.
Drugs and US Patents for Beigene
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,884,674 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,591,340 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 9,447,106 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,142,528 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 10,570,139 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Beigene Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Cyprus | 1118834 | ⤷ Try a Trial |
Australia | 2017314178 | ⤷ Try a Trial |
New Zealand | 751418 | ⤷ Try a Trial |
Australia | 2022200278 | ⤷ Try a Trial |
China | 109563099 | ⤷ Try a Trial |
South Korea | 20160002812 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Beigene Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2989106 | C202230011 | Spain | ⤷ Try a Trial | PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122 |
2989106 | 301161 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
2989106 | C02989106/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: BEIGENE, LTD., KY |
2989106 | 22C1010 | France | ⤷ Try a Trial | PRODUCT NAME: ZANUBRUTINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1576 20211123 |
2989106 | 2290500-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1576 20211123 |
2989106 | 2022C/508 | Belgium | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.